Moreover, miR-155-3p has also been demonstrated to directly inhibit homeobox protein SIX1 in glioma, with reintroduction of SIX1 found to rescue the TMZ resistance induced by miR-155-3p mimic administration [100]. Here, SIX1 is linked to central nervous system cancer.